Recent Finacing
Recent Raise
Azafaros is a clinical-stage company developing orally available, brain-penetrant azasugar molecules licensed from Leiden/Amsterdam UMC to treat CNS lysosomal storage disorders (GM1/GM2, NPC), advancing lead toward Phase 3.
